FDA Form 483 is issued at the conclusion of an FDA inspection to document observed conditions that may constitute regulatory violations or significant compliance concerns.
In clinical trials, observations frequently involve informed consent issues, protocol noncompliance, inadequate documentation, or weak investigational product controls. Sponsors and sites are expected to respond with a documented remediation plan, often including CAPA actions with timelines and root cause analysis. Prompt, thorough responses help mitigate regulatory risk and demonstrate commitment to corrective action. Effective resolution supports ongoing trial integrity and inspection readiness.